Drugs.com - Clinical Trials

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study

Malmö, Sweden 18 December 2024 PILA PHARMA AB (publ) (“PILA PHARMA” or the “Company”) today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden...

Feb 9, 2025 - 21:44
 0
Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study
Malmö, Sweden 18 December 2024 PILA PHARMA AB (publ) (“PILA PHARMA” or the “Company”) today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden...
Read More

Tags:

Previous Article

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggest...

Next Article

Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal S...

Related Posts

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan ...

Mar 26, 2025  0

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

Sapience Therapeutics Receives FDA Orphan Drug Designat...

Feb 9, 2025  0

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation f...

Feb 9, 2025  0